Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value
Author:
Affiliation:
1. Institute for Clinical and Economic Review, Boston, MA.
2. Department of Medicine and Philip R Lee Institute for Health Policy Studies, University of California, San Francisco.
Publisher
Academy of Managed Care Pharmacy
Subject
Health Policy,Pharmaceutical Science,Pharmacy
Reference12 articles.
1. Multiple Sclerosis
2. The prevalence of MS in the United States
3. The Economic Burden of Multiple Sclerosis in the United States
4. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
5. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy;Drug Design, Development and Therapy;2024-07
2. Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study;Annals of Neurology;2024-03-26
3. A Comprehensive Review of Anti-CD20 Monoclonal Antibodies in Multiple Sclerosis;International Journal of Pharmaceutical And Phytopharmacological Research;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3